Clinical Info

Wang, et al Clinical Study: data on file awaiting publication date.

This clinical study (2017-2020) with mild DR patients was conducted at Bascom Palmer Eye Institute (U of Miami) and showed the following:

• Improvement in retinal tissue perfusion (RTP)
• Best responders were patients with folate-related polymorphisms

Liu, et al Clinical Study: Macrovascular Research (2020)

This clinical study (2017-2020) with mild DR patients was conducted at Bascom Palmer Eye Institute (U of Miami) and showed the following:

• Improvement in conjunctival microcirculation and microvascular markers
• Improvement in Best Corrected Visual Acuity (BCVA)
• Homocysteine (Hcy) and oxidative stress were reduced
• Best responders were patients with folate-related polymorphisms

Shi, et al Clinical Study: Eye and Vision (2020)

Much of the above clinical improvements were derived from addressing the underlying nutritional deficiencies that are common among many patients with retinal ischemia such as mild diabetic retinopathy.

• Role of Elevated Homocysteine (Hcy) in progressive eye disease
• Impact of genetic polymorphisms to progressive eye disease

Changes in vision for Diabetic Retinopathy patients can improve in as little as six Months as seen in the study conducted at Bascom Palmer Eye institute and in the AR practice of Dr Craig Brown (Eye Center of Fayetteville).

Patients showed improvement at both 3 months and 6 months as compared to the expected deterioration of sight over time. We feel that better eyesight can be expected after a perfusion of both retinal and conjunctival tissue with improved retinal blood flow over that time period.

Schmidl, et al Clinical Study: Molecular Vision (2020) 

This Clinical Study was performed by the Department of Clinical Pharmacology at Medical University of Vienna. They investigated three-month active folate supplementation (with the same L-methylfolate ingredient as used in Ocufolin) as a means to manage homocysteine levels in type 2 diabetic patients. NOTE: This study was dosed at only one capsule per day rather than the three capsules daily recommended for Ocufolin.

• After 3 months, plasma Hcy levels were significantly decreased (14.6 umol to 9.6 umol)
• After 3 months, active patients showed a tendancy toward increased retinal blood flow (36.8 ul/min to 39.2 ul/min)

Ocufolin™ has a recommended retail cost to patients of $50/ month. Ocufolin™ is a medical food and should only be used under medical supervision. Wholesale orders are available to U.S. HCP offices and at local pharmacies. Please contact us for details and/or a wholesale order form.

Global Healthcare Focus, LLC believes that Ocufolin™ provides an effective solution to this modern health concern. We provide a product of excellent quality and the right dose. Better still, we cut out the “middleman” and can protect the price to the patient. Ocufolin™ delivers real value that you can trust.